Dai Xuan, Wang Haoran, Lu Yaqi, Chen Yan, Liu Yun, Huang Shiyong
Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
The First Clinical School, Xinxiang Medical University, Xinxiang 453003, China.
Cancers (Basel). 2023 Nov 29;15(23):5643. doi: 10.3390/cancers15235643.
We aimed to develop a clinical predictive model for predicting the overall survival (OS) in stage I-III CRC patients after radical resection with normal preoperative CEA. This study included 1082 consecutive patients. They were further divided into a training set (70%) and a validation set (30%). The selection of variables for the model was informed by the Akaike information criterion. After that, the clinical predictive model was constructed, evaluated, and validated. The net reclassification index (NRI) and integrated discrimination improvement (IDI) were employed to compare the models. Age, histologic type, pT stage, pN stage, carbohydrate antigen 242 (CA242), and carbohydrate antigen 125 (CA125) were selected to establish a clinical prediction model for OS. The concordance index (C-index) (0.748 for the training set and 0.702 for the validation set) indicated that the nomogram had good discrimination ability. The decision curve analysis highlighted that the model has superior efficiency in clinical decision-making. NRI and IDI showed that the established nomogram markedly outperformed the TNM stage. The new clinical prediction model was notably superior to the AJCC 8th TNM stage, and it can be used to accurately assess the OS of stage I-III CRC patients undergoing radical resection with normal preoperative CEA.
我们旨在开发一种临床预测模型,用于预测术前癌胚抗原(CEA)正常的I-III期结直肠癌(CRC)患者根治性切除术后的总生存期(OS)。本研究纳入了1082例连续患者。他们被进一步分为训练集(70%)和验证集(30%)。模型变量的选择依据赤池信息准则。之后,构建、评估并验证了临床预测模型。采用净重新分类指数(NRI)和综合判别改善(IDI)来比较模型。选择年龄、组织学类型、pT分期、pN分期、糖类抗原242(CA242)和糖类抗原125(CA125)来建立OS的临床预测模型。一致性指数(C指数)(训练集为0.748,验证集为0.702)表明列线图具有良好的判别能力。决策曲线分析表明该模型在临床决策中具有更高的效率。NRI和IDI显示,所建立的列线图明显优于TNM分期。新的临床预测模型明显优于美国癌症联合委员会(AJCC)第8版TNM分期,可用于准确评估术前CEA正常的I-III期CRC根治性切除患者的OS。